Variable | All cases | Mean survival (months) | Median survival (months) | P value |
---|---|---|---|---|
Age at surgery | 0.75 | |||
≤ 51a | 54 | 74.4 | NRb | |
> 51 | 48 | 92.9 | NRb | |
Histological type | ||||
Serous | 72 | 78.4 | NRb | 0.55 |
Mucinous | 11 | 62.7 | 45 | |
Othersc | 19 | 88.4 | NRb | |
Histologicalgrade (Silveberg) | 0.00 | |||
G1 | 16 | 116.3 | NRb | |
G2 | 61 | 87.5 | NRb | |
G3 | 25 | 33.3 | 22 | |
FIGO stage | 0.00 | |||
I | 19 | 57.2 | NRb | |
II | 10 | 59.1 | NRb | |
III | 58 | 34.1 | NRb | |
IV | 15 | 21.6 | NRb | |
Operation | 0.00 | |||
Satisfactory cytoreductive operation | 35 | 92.3 | NRb | |
Stage operation | 32 | 121.4 | NRb | |
Unsatisfactory cytoreductive operation | 25 | 47.6 | 22 | |
Chemical program | 0.17 | |||
TP | 17 | 62.0 | NRb | |
Cyclophosphamide + Adriamycin + Carbo | 41 | 83.5 | 66 | |
Others | 44 | 63.6 | NRb | |
Residual tumor | 0.00 | |||
None | 32 | 121.2 | NRb | |
<=2cm | 35 | 92.3 | NRb | |
>2cm | 35 | 46.5 | 22 | |
CHD1L protein expression | 0.03 | |||
Negative | 50 | 97.4 | NRb | |
Positive | 52 | 66.7 | 37 |